The FDA approved Scinopharm's glatiramer acetate injection, a generic version of Copaxone, to treat multiple sclerosis.

Copaxone is available in two strengths: 20 milligrams (mg) per 1 milliliter (mL) of liquid solution and 40 mg/mL. The drug comes in single-dose prefilled syringes for injection under the skin. For all ...

AHMEDABAD, India, May 08, 2025--(BUSINESS WIRE)--Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as "Zydus") has received final approval from the United ...

COPAXONE ® (Glatiramer Acetate injection) is indicated for the treatment of patients with relapsing forms of multiple sclerosis. The most common side effects of COPAXONE ® are redness, pain, swelling, ...

The US Food and Drug Administration (FDA) is adding the risk of anaphylaxis to a new boxed warning of glatiramer acetate, a medicine for multiple sclerosis (MS). The agency issued the warning about ...

Medically reviewed by Brigid Dwyer, MD Key Takeaways Disease-modifying therapies slow down the progression of multiple sclerosis. Beta interferon drugs reduce MS attacks by altering the immune ...

Novartis’ Sandoz has received US approval for the first generic form of Teva's multiple sclerosis blockbuster Copaxone (glatiramer acetate). Novartis’ Sandoz has received US approval for the first ...

A new MS drug Copaxone shows promise in reducing heart attack risk, offering potential benefits beyond multiple sclerosis for heart health and patient outcomes. A groundbreaking discovery in the 1960s ...

Copaxone (glatiramer acetate) may not be safe to receive while pregnant or breastfeeding. Certain factors, including the risks of fetal harm, may determine whether you can receive the drug during this ...

Disease-Modifying Therapy Comparison and Side Effects ...